In this article, we will look at the 10 Fastest Growing NASDAQ Stocks to Buy.
High-growth stocks have once again taken center stage, and major asset managers contend that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P. Morgan Asset Management notes that “profit growth has been impressive, tracking for four consecutive quarters of double-digit earnings growth”. The firm adds that “within stocks, we continue to see the biggest opportunities in structural rather than cyclical stories”, underscoring a preference for companies benefiting from secular tailwinds. Artificial intelligence remains a major catalyst behind this structural growth. J.P. Morgan writes that “the investment and adoption of AI continues to dominate the strength seen in U.S. economic and earnings growth”.
Vanguard’s 2026 Economic and Market Outlook echoes this constructive stance on growth, stating that “U.S. technology stocks could well maintain their momentum given the rate of investment and anticipated earnings growth.” At the same time, Vanguard cautions that “risks are growing amid this exuberance,” highlighting the need for selectivity.
Taken together, these outlooks suggest that fast-growing companies with sustained revenue acceleration and clear structural drivers remain compelling. With growth serving as the engine of returns, the focus shifts to businesses capable of compounding at elevated rates rather than merely benefiting from earnings multiple expansion. Against this backdrop, we’ll look at the 10 Fastest Growing NASDAQ Stocks to Buy.
Our Methodology
We used the Finviz screener to identify stocks that have achieved more than 50% sales growth over the past year and more than 50% growth over the past three years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. Brookfield Asset Management Ltd. (NYSE:BAM)
On February 17, 2026, Morgan Stanley raised its price target on Brookfield Asset Management to $63 from $62 and maintained an Equal Weight rating, updating its model following the Q4 report.
Earlier in February, Brookfield Asset Management reported Q4 EPS of 47c, compared to the 44c consensus estimate. Fee-bearing capital grew to $603B, up 12% year over year, driven by record quarterly fundraising of $35B and $112B in the last year. CEO Connor Teskey said, “2025 was another record year for our business,” citing results “across each of fundraising, deployment, and monetizations.” He added that fee-bearing capital grew “to over $600B,” with “22% year-over-year growth in fee-related earnings” and “14% growth in distributable earnings.” Teskey said the company will have “key flagship strategies in the market” and a “growing suite of complementary offerings,” which supports the decision “to increase our dividend by 15%.”
The board declared a quarterly dividend of 50.25c per share, representing a 15% increase, payable on March 31 to shareholders of record as of the close of business on February 27.
Brookfield Asset Management Ltd. (NYSE:BAM) is a private equity firm specializing in acquisitions and growth capital investments, typically investing in renewable power, transition, and infrastructure sectors.
9. Hims & Hers Health, Inc. (NYSE:HIMS)
On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48 and kept an Overweight rating on the shares. That same day, TD Cowen analyst Jonna Kim lowered the firm’s price target to $17 from $20 and maintained a Hold rating, citing near-term pressure until there is more clarity on regulatory implications around compounded injectable GLP-1s and improvement in the underlying core business momentum.
Morgan Stanley analyst Craig Hettenbach also reduced the firm’s price target to $21 from $40 and kept an Equal Weight rating. The analyst said 2026 revenue guidance “surprisingly” came in about 2% ahead of the Street view, but EBITDA guidance was about 8% below consensus, confirming concerns about increased investment.
On February 23, 2026, Hims & Hers Health reported Q4 EPS of 8c, compared to the 19c consensus estimate. Q4 revenue was $617.82M, versus consensus of $617.25M. Co-founder and CEO Andrew Dudum said, “More than 2.5 million subscribers now rely on us,” adding the company believes it is “well on our way to becoming the global leader in consumer health.” Dudum stated that in 2025 the company expanded access to care “across an expanding range of conditions,” including “launching hormone therapies and diagnostics” and “introducing Labs,” while taking steps “to grow internationally.” He added that the “continued growth and diversification of our platform” supports proactive and personalized care.
Hims & Hers Health, Inc. (NYSE:HIMS) operates a consumer-first health and wellness platform connecting consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
8. Primo Brands Corporation (NYSE:PRMB)
On February 27, 2026, RBC Capital analyst Nik Modi raised the price target on Primo Brands Corporation (NYSE:PRMB) to $29 from $26 and maintained an Outperform rating. The analyst said the company reported solid upside to estimates in Q4, driven by less severe declines in the delivery business, calling the result “a step in the right direction” that increases confidence in the company’s recovery.
That same day, JPMorgan raised its price target on Primo Brands to $27 from $21 and kept an Overweight rating, updating its model following the Q4 report. The firm said Primo reported “better-than-feared” results in its Direct Delivery business and that guidance “appears beatable.”
On February 26, 2026, Primo Brands reported Q4 adjusted EPS of 26c, compared to 13c last year. Q4 revenue was $1.554B versus $1.397B last year. Chairman and Chief Executive Officer Eric Foss said, “2025 was a year of transition,” as the company integrated two businesses to form a leader in healthy hydration across the U.S. Liquid Refreshment Beverage category. He added that the fourth quarter performance showed “early signs” that initiatives are resulting in “an improved trajectory for the business,” reflecting the “strength and resilience” of the business model.
Primo Brands Corporation (NYSE:PRMB) operates as a branded beverage company in North America, offering water dispensers, direct delivery of refillable and reusable bottles, a pre-filled Water exchange program, water filtration appliances, and self-service water refill stations.
7. LandBridge Company LLC (NYSE:LB)
On February 27, 2026, Barclays raised its price target on LandBridge Company LLC (NYSE:LB) to $75 from $57 and maintained an Equal Weight rating, citing a strong Q4 report.
On February 25, 2026, LandBridge’s Board of Directors approved a two-year share repurchase authorization allowing the company to opportunistically repurchase up to $50 million of Class A shares. The authorization is intended to provide opportunities to acquire shares at levels the company believes do not reflect its fundamental earnings power and to enable incremental capital return to shareholders.
That same day, LandBridge reported Q4 revenue of $56.8M, compared to the $49.25M consensus estimate. Chief Executive Officer Jason Long said, “We entered 2026 with strong momentum,” and noted the company continues “to shift the paradigm of active land management.” He added that with “over 315,000 optimally-located and largely contiguous surface acres,” the company supports energy, power, digital infrastructure and broader industrial development. Long stated that LandBridge has a “strong balance sheet” and a “proven platform for organic and acquisition-driven expansion,” and is “well positioned to deliver differentiated value to shareholders.”
LandBridge Company LLC (NYSE:LB), together with its subsidiaries, owns and manages land and resources to support and enhance oil and natural gas development in the United States.
6. Circle Internet Group (NYSE:CRCL)
On February 26, 2026, Deutsche Bank raised its price target on Circle Internet Group (NYSE:CRCL) to $75 from $71 and maintained a Hold rating on the shares.
That same day, Mizuho analyst Dan Dolev raised the firm’s price target to $90 from $77 and kept a Neutral rating. The analyst said the company reported solid Q4 results, with better than expected revenue and profits, and updated the model to reflect the “strong” Q4 report and 2026 outlook.
On February 25, 2026, Circle Internet reported Q4 EPS of 43c, compared to the 25c consensus estimate. Q4 revenue was $770.23M versus the consensus of $744.95M. Co-Founder, Chief Executive Officer, and Chairman Jeremy Allaire said, “The fourth quarter marked another step forward in Circle’s mission to build the infrastructure for an open, programmable internet financial system.” He noted that “USDC adoption continued to expand globally” as enterprises, developers, and public institutions integrated digital dollars into payments and treasury workflows. Allaire added that the company saw “strong engagement across our platform,” “meaningful progress toward launching Arc mainnet,” continued growth in CPN TPV, and “growing momentum for EURC and USYC,” stating that Circle is helping build “a more open and resilient global financial system.”
Circle Internet Group (NYSE:CRCL) operates as a platform, network, and market infrastructure for stablecoin and blockchain applications.
5. D-Wave Quantum Inc. (NYSE:QBTS)
On February 27, 2026, Evercore ISI analyst Mark Lipacis lowered the price target on D-Wave Quantum Inc. (NYSE:QBTS) to $42 from $44 and maintained an Outperform rating on the shares.
That same day, Mizuho analyst Vijay Rakesh reduced the firm’s price target to $40 from $46 and kept an Outperform rating, updating the model following the earnings report.
On February 26, 2026, D-Wave Quantum reported Q4 adjusted EPS of (9c), compared to the (6c) consensus estimate. Q4 revenue was $2.75M versus the $3.74M consensus. Bookings for Q4 totaled $13.4M. Chief Executive Officer Alan Baratz said 2025 marked “one of the most successful and transformative years” in the company’s history, citing growth across “revenue, Bookings, technical milestones, and scientific breakthroughs.” He added that the company is entering 2026 with “exceptional momentum,” generating “over $30 million in Bookings in January alone,” expanding market leadership through the acquisition of Quantum Circuits, Inc., and securing “an eight-figure enterprise QCaaS agreement,” which he said underscores growing customer confidence. Baratz stated that “2026 is shaping up to be a defining year for D-Wave.”
D-Wave Quantum Inc. (NYSE:QBTS) develops and delivers quantum computing systems, software, and services worldwide, including Advantage and Advantage 2 quantum computers, the Ocean open-source tools suite, and the Leap quantum cloud service.
4. ImmunityBio, Inc. (NASDAQ:IBRX)
On February 23, 2026, H.C. Wainwright raised its price target on ImmunityBio, Inc. (NASDAQ:IBRX) to $15 from $10 and maintained a Buy rating on the shares. The analyst said the recent European Union approval expands Anktiva’s footprint to 33 countries, “removing a major regulatory overhang” and opening a “meaningful incremental commercial opportunity.”
That same day, ImmunityBio reported Q4 EPS of (6c), compared to the (10c) consensus estimate. Q4 revenue was $38.29M versus consensus of $37.78M. President and CEO Richard Adcock said the company’s 2025 financial results reflect the growing clinical adoption of Anktiva “as a foundational backbone of immunotherapy for bladder cancer.” He noted that the partnership with Accord Healthcare deploys over 100 commercial professionals across 30 European countries and that collaboration with BioPharma & Cigalah supports commercial execution in Saudi Arabia and the broader MENA region. Adcock stated that with subsidiaries in Dublin and the Kingdom of Saudi Arabia, the company has infrastructure to support growth across all 33 countries where Anktiva is authorized. He added that the company remains focused on completing enrollment in its BCG-naive randomized trial with a BLA filing targeted by Q4 2026, expanding the Anktiva label into lung cancer and lymphopenia, and converting its “700% revenue growth trajectory” into durable value for shareholders.
ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing next-generation immunotherapies for cancer and infectious diseases.
3. CoreWeave, Inc. (NASDAQ:CRWV)
On February 27, 2026, Truist analyst Arvind Ramnani raised the price target on CoreWeave, Inc. (NASDAQ:CRWV) to $85 from $84 and maintained a Hold rating following Q4 results. The analyst said demand continues to significantly outpace supply, but questioned “at what cost this will come,” adding there are more questions about the path to long-term sustainable profitability.
That same day, DA Davidson raised its price target to $125 from $110 and kept a Buy rating. The firm cited strong Q4 earnings driven by continued demand for AI compute and noted management’s forecast for 2026 capex in the $30B-$35B range compared to $14.9B in 2025. DA Davidson said that in a market where bringing capacity online is a key measure of success, capital expenditures and active power guidance serve as indicators of future performance.
On February 26, 2026, CoreWeave reported Q4 EPS of (89c), compared to the (68c) consensus estimate. Q4 revenue was $1.57B versus consensus of $1.53B. Chairman and Chief Executive Officer Michael Intrator said 2025 was “a defining year” as the company became “the fastest cloud in history to reach $5 billion in annual revenue,” adding that demand continues to intensify, and the company is ready to capture the opportunity ahead. Chief Financial Officer Nitin Agrawal said revenue backlog grew to $66.8 billion, “more than four times” where it began the year, providing visibility as the company scales into 2026 and beyond, and stated that CoreWeave is “well positioned for sustained hypergrowth.”
CoreWeave, Inc. (NASDAQ:CRWV) operates a cloud platform providing scaling, support, and acceleration for GenAI and builds infrastructure to support enterprise compute workloads.
2. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
On February 27, 2026, Guggenheim raised its price target on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) to $35 from $34 and maintained a Buy rating. The firm said it remains “encouraged” by the trajectory of Zoryve and the company’s efforts to maximize its value through commercialization.
On February 26, 2026, TD Cowen raised its price target to $35 from $30 and kept a Buy rating, updating its model following Q4 results as management increased full-year 2026 guidance.
On February 25, 2026, Arcutis Biotherapeutics reported Q4 EPS of 13c, compared to the 9c consensus estimate. Q4 revenue was $129.5M versus consensus of $113.03M. President and Chief Executive Officer Frank Watanabe said that in 2025, the company delivered more than 90% year-over-year growth in net product revenue, reflecting demand for ZORYVE, execution across multiple product launches leveraging its differentiated profile, and early penetration into the topical steroid market. Watanabe added that the company is entering the next phase of growth with a solid cash position and resources to invest in ZORYVE’s continued growth and pipeline advancement.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases.
1. Viridian Therapeutics, Inc. (NASDAQ:VRDN)
On February 27, 2026, RBC Capital lowered its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The analyst noted the company reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June 30, with preparations underway for a potential commercial launch in thyroid eye disease in mid-2026 if approved. RBC said it continues to favor the company’s positioning in 2026 as it could transition to the commercial stage and move closer to profitability.
On February 26, 2026, Jefferies raised its price target to $45 from $44 and kept a Buy rating. The firm said all key events remain on track and that investor focus is on the Phase 3 topline readout of subcutaneous elegrobart in REVEAL-1 in Q1, REVEAL-2 in Q2, and the PDUFA decision due June 30 for intravenous veligrotug under priority review.
That same day, Viridian Therapeutics reported Q4 EPS of ($1.08), compared to the ($1.00) consensus estimate. Q4 revenue was $132,000 versus the consensus of $15.75M. President and Chief Executive Officer Steve Mahoney said the company enters 2026 with continued execution momentum, highlighting the veligrotug BLA filing under Priority Review and a June 30, 2026, PDUFA target date. He added that the MAA submission to the EMA supports the global opportunity for veligrotug and that REVEAL-1 topline data for elegrobart is expected next month, with the goal of establishing veligrotug and elegrobart as foundational therapies for TED while advancing the broader pipeline.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) discovers, develops, and commercializes treatments for serious and rare diseases, including IGF-1R therapies for thyroid eye disease.
While we acknowledge the potential of VRDN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VRDN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
